Cargando…
Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target
Currently, the world suffers from a new coronavirus SARS-CoV-2 that causes COVID-19. Therefore, there is a need for the urgent development of novel drugs and vaccines for COVID-19. Since it can take years to develop new drugs against this disease, here we used a hybrid combined molecular modeling ap...
Autor principal: | DURDAĞI, Serdar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314512/ https://www.ncbi.nlm.nih.gov/pubmed/32595355 http://dx.doi.org/10.3906/biy-2005-112 |
Ejemplares similares
-
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
por: Baby, Krishnaprasad, et al.
Publicado: (2021) -
TMPRSS2, a novel host-directed drug target against SARS-CoV-2
por: Keller, Christian, et al.
Publicado: (2022) -
Targeting TMPRSS2 in SARS-CoV-2 Infection
por: Baughn, Linda B., et al.
Publicado: (2020) -
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021) -
Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease
por: OKTAY, Lalehan, et al.
Publicado: (2021)